Novartis to expand cardiovascular drug portfolio with $1.4B deal

Novartis is acquiring biopharmaceutical company Tourmaline Bio for $1.4 billion to boost its cardiovascular pipeline. 

Tourmaline develops pacibekitug, a drug used to treat atherosclerotic cardiovascular disease, according to a Sept. 9 news release from Novartis. 

Novartis said the drug is in advanced phase 2 clinical trials and works to combat residual inflammatory risk more effectively than current therapies. The drug is being added to the drugmaker’s existing cardiovascular therapy portfolio, the release said. 

The post Novartis to expand cardiovascular drug portfolio with $1.4B deal appeared first on Becker’s Hospital Review | Healthcare News & Analysis.